A Phase 1/2 study of induction therapy with Thalidomide, Melphalan and Prednisolone for newly diagnosed multiple myeloma patients ineligible for hematopoietic stem cell transplantation

Trial Profile

A Phase 1/2 study of induction therapy with Thalidomide, Melphalan and Prednisolone for newly diagnosed multiple myeloma patients ineligible for hematopoietic stem cell transplantation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Thalidomide (Primary) ; Melphalan; Prednisolone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Fujimoto Pharmaceutical
  • Most Recent Events

    • 16 Jun 2016 New trial record
    • 30 Jul 2015 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top